BeOne Medicines (ONC) Depreciation & Amortization (CF) (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $41.1 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 25.42% year-over-year to $41.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $150.0 million (down 16.31% YoY) and the FY2025 annual result came in at $141.7 million, down 17.51% from the prior year.
• Depreciation & Amortization (CF) improved to $41.1 million in Q1 2026 per ONC's latest filing, from $36.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $71.3 million in Q3 2024 and bottomed at $15.5 million in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $24.9 million (2024), against an average of $29.9 million.
• The widest annual swing landed in 2024, when Depreciation & Amortization (CF) jumped 231.44%; it then tumbled 47.7% in 2025.
• Tracing ONC's Depreciation & Amortization (CF) over 5 years: stood at $18.0 million in 2022, then soared by 32.21% to $23.8 million in 2023, then soared by 110.95% to $50.2 million in 2024, then slipped by 28.38% to $36.0 million in 2025, then climbed by 14.34% to $41.1 million in 2026.
• Per Business Quant, the three latest ONC Depreciation & Amortization (CF) figures stand at $41.1 million (Q1 2026), $36.0 million (Q4 2025), and $37.3 million (Q3 2025).

Peer Comparison